Cancer Communications (Feb 2023)

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

  • Yuanyuan Zhao,
  • Bing Zhao,
  • Gang Chen,
  • Yinlan Chen,
  • Zijun Liao,
  • Haiming Zhang,
  • Weineng Feng,
  • Yinyin Li,
  • Heng Weng,
  • Weidong Li,
  • Yuefen Zhou,
  • Biyong Ren,
  • Yanda Lu,
  • Jianhua Chen,
  • Zhenteng Liu,
  • Zhenzhong Su,
  • Wenliang Wang,
  • Li Zhang

DOI
https://doi.org/10.1002/cac2.12397
Journal volume & issue
Vol. 43, no. 2
pp. 246 – 256

Abstract

Read online

Abstract Background Highly emetogenic chemotherapy induces emesis in cancer patients without prophylaxis. The purpose of this study was to evaluate the efficacy and safety of a fosaprepitant‐based triple antiemetic regimen for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients with solid malignant tumors, determine risk factors and externally validate different personalized risk models for CINV. Methods This phase III trial was designed to test the non‐inferiority of fosaprepitant toward aprepitant in cancer patients who were to receive the first cycle of single‐day cisplatin chemotherapy. The primary endpoint was complete response (CR) during the overall phase (OP) with a non‐inferiority margin of 10.0%. Logistic regression models were used to assess the risk factors of CR and no nausea. To validate the personalized risk models, the accuracy of the risk scoring systems was determined by measuring the specificity, sensitivity and area under the receiver operating characteristic (ROC) curve (AUC), while the predictive accuracy of the nomogram was measured using concordance index (C‐index). Results A total of 720 patients were randomly assigned. CR during the OP in the fosaprepitant group was not inferior to that in the aprepitant group (78.1% vs. 77.7%, P = 0.765) with a between‐group difference of 0.4% (95% CI, ‐5.7% to 6.6%). Female sex, higher cisplatin dose (≥ 70 mg/m2), no history of drinking and larger body surface area (BSA) were significantly associated with nausea. The AUC for the acute and delayed CINV risk indexes was 0.68 (95% CI: 0.66‐0.71) and 0.66 (95% CI: 0.61‐0.70), respectively, and the C‐index for nomogram CINV prediction was 0.59 (95% CI, 0.54‐0.64). Using appropriate cutoff points, the three models could stratify patients with high‐ or low‐risk CINV. No nausea and CR rate were significantly higher in the low‐risk group than in the high‐risk group (P < 0.001). Conclusions Fosaprepitant‐based triple prophylaxis demonstrated non‐inferior control for preventing CINV in patients treated with cisplatin‐base chemotherapy. Female cancer patients without a history of alcohol consumption, with larger BSA and received high‐dose cisplatin might be more vulnerable to CINV. Three personalized prediction models were well‐validated and could be used to optimize antiemetic therapy for individual patients.

Keywords